Commercial-Ready Product with International Patent Filed

CQ1 (Mentabinol®) – As per CanaQuest’s September 17, 2019, press release, this game-changing discovery, Mentabinol®, protects consumers from acute & long-term negative psychiatric side effects of THC intake. This formulation utilizing Food-Grade Botanical Extract “BX” and extracted THC oil from the marijuana “MJ” plant addresses four major problems resulting from consuming THC for an extended time.

The application of Mentabinol® in pre-clinical trials at Western University have demonstrated:

  • Reversal of depression-like and schizophrenia related symptom effects;
  • Complete blockage of memory impairment;
  • Complete blockage of hyperactive activity;
  • Complete blockage of gene vulnerability.

Mentabinol® provides an alternative to Opioids.

The discovery was made by a research team led by Dr. Steven Laviolette, neuroscientist, at Western University, leading one of the two sponsored research programs that CanaQuest currently has with prominent Canadian universities.




A critical mass of clinical evidence regarding the efficacy of medical cannabis is refuting political, scientific, and other skeptics, and opening minds hardened by decades of anti-cannabis propaganda. Our goal is to develop better alternative treatments to traditional pharmaceuticals for people struggling with a variety of health challenges.

CQ1 (Mentabinol®)

  • Commercial Ready (THC + formula)
  • Supports mental health: anxiety, depression, and schizophrenia.

CQ2 (Mentanine®)

  • Commercial Ready (Omega 3 + formula)
  • Supports mental health: Anxiety, depression, PTSD and addiction.

CQ3(Mentanine – pain®)

  • Coming soon (Omega 3 + formula)
  • To support endocannabinoid system health: Inflammation and pain.


  • Coming soon
  • To support mental health: Alzheimer’s